Aspirin in Reducing Events in the Elderly

Study aims

ASPREE is a placebo-controlled trial of low-dose aspirin. The primary aim of the study is to determine whether 5 years of daily daily 100-mg enteric-coated aspirin can prolong disability-free survival and dementia-free life in a healthy elderly population when used in a primary prevention setting.



Year commenced


No. follow up

Average 5 waves



Baseline sample size

16,703 Australian and 2,411 U.S.


In Australia, recruitment was mostly based in general practice (family practice) with the participant’s usual primary care (family) physician enrolled as a study coinvestigator. In the United States, recruitment was community based through academic and clinical trial centers.

Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin.




Demography, lifestyle, health & medical, social, physical function, depression, cognition, activities of daily living, genetic, biomarkers.

Data collection

Questionnaires, telephone interviews, cardiovascular assessments, neurocognitive assessments, physical function assessments, MRI scans, blood tests, blood samples, urine samples, buccal swabs

Type of dementia

Dementia (AD, VaD, other dementias), MCI

Cognitive assessment

3MS, HVLT-R, SDMT, COWAT, ADAS-COG, Color Trails, CAM, ADCS-ADL with surrogate

Dementia & type, adjudicated by a panel of experts

Location of research

Australia: South-eastern area (including Adelaide, Canberra, Melbourne, Hobart and 20 regional centres).

U.S. 28 centres across the country 

Contact person

Dr. Joanne Ryan

Contact details

This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

Web address

Funding agencies

NIH, NHMRC, Monash University

Data availability

Needs approval from the ASPREE Investigator management committees.